Overview: Disseminated Intravascular Coagulation Profile
Introduction: The Disseminated Intravascular Coagulation Profile is a diagnostic tool designed to diagnose disseminated intravascular coagulation using plasma samples. In India, DIC is common in sepsis (bacterial, malaria, dengue), trauma, obstetric complications, malignancy, and snakebite, with high mortality (~40-60 percent in severe cases) due to bleeding and thrombosis. High burden from underdiagnosis in rural critical care settings, limited coagulation labs, delayed fresh frozen plasma/cryoprecipitate leading to multi-organ failure. Per hematology practices aligned with ICMR and Indian Society of Critical Care Medicine guidelines, the test employs coagulation analyzer for comprehensive profile (PT, aPTT, INR, D-dimer, fibrinogen, platelets, factors) over 1-2 days with high accuracy, valuable for scoring and monitoring. This diagnostic falls under coagulation disorder screening and targets critically ill patients with bleeding/thrombosis, addressing accurate detection to guide supportive therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing DIC mortality. Its plasma-based approach ensures reliable coagulation assessment.
Other Names: DIC Pnl.
FDA Status: FDA approved, CLIA certified for hematology, compliant with 2025 standards.
Historical Milestone: ISTH DIC score standard; in India, used in sepsis protocols.
Purpose: The test assesses 28 parameters including PT and D-dimer to guide DIC diagnosis, monitor consumption, inform replacement therapy.
Test Parameters: 1. PT, 2. aPTT, 3. INR, 4. D-Dimer, 5. Fibrinogen, 6. Platelet Count, 7â€"28. Coagulation Factors and Markers.
Pretest Condition: No fasting required; patients should report bleeding, thrombosis, or sepsis signs.
Specimen: 3 mL plasma in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on underlying condition (sepsis, trauma, obstetric), bleeding sites.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated DIC including hemorrhage, benefits of early detection, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using coagulation analyzer by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or anticoagulants can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal profile indicates DIC, necessitating specialist input. Normal may require follow-up if suspicion high.
Specialist Consultation: Hematologists or intensivists should be consulted for management.
Additional Supporting Tests: ISTH score, fibrinogen degradation products for confirmation.
Test Limitations: Dynamic condition; comprehensive approach required.
References: Indian Journal of Critical Care Medicine 2024, DIC Studies India 2023.
